EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Chemoproteomic discovery of a brain‐penetrant, covalent NLRP3 inhibitor that binds a novel allosteric pocket

Donald C Rogness, Evelyn P Sievert iD, Vincent F Vartabedian, Steffen M Bernard, Erick Aitchison, William Tao, Mikaela Lindvall, Jing Qian, Christie L Eissler, Brian E Nordin, Benjamin D Horning, Cian Kingston und 10 weitere

British Journal of Pharmacology · 2026

DOI: 10.1111/bph.70626 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, 2026. Verfasst von Donald C Rogness und 21 weiteren Autor:innen. Beteiligte Einrichtung: Vividion Therapeutics, San Diego, California, USA. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Brain. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose The NLRP3 inflammasome is an attractive therapeutic target for multiple inflammatory conditions. Although inhibitors have been developed, their chemical diversity is limited, and their properties are not ideal for brain penetrance, which is desirable for treating neuroinflammatory disorders. Experimental Approach We applied our chemoproteomics platform to survey our electrophilic fragment collection to identify inhibitors of NLRP3. We focused our attention on compounds that bind Cys463, as this residue was identified as an allosteric sensor of NLRP3 function. Key Results A novel inhibitor series was identified bearing a butynamide electrophile and a unique spirocyclic lactam core. Compounds from this series displayed mid‐nanomolar potency and were found to inhibit IL‐1β secretion in a Cys463‐dependent manner. Cryo‐EM structures revealed that ligand binding to Cys463 stabilizes an inactive conformation, thereby preventing structural rearrangements required for inflammasome activation. These compounds displayed attractive pharmacokinetic properties and, notably, Kp,uu values >0.5, suggesting the potential to address neuroinflammatory disorders. Administration of a representative compound to humanized mice resulted in clear NLRP3 Cys463 target‐engagement and profound suppression of LPS‐ and ATP‐induced IL‐1β secretion, demonstrating clear proof‐of‐concept in vivo. Conclusion and Implications Chemoproteomics‐based ligand discovery is intrinsically function‐agnostic and has the potential to identify novel pockets on even well‐characterized protein targets. Here, optimization of ligands targeting Cys463 of NLRP3 within a previously uncharacterized allosteric pocket led to a unique and potent inhibitor series with attractive physicochemical and pharmacokinetic properties for the potential treatment of diseases involving aberrant innate immune activation in both central and peripheral tissues. LINKED ARTICLES This article is part of a themed issue Re‐emergence of Covalent Modulation in Drug Discovery. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v183.22/issuetoc

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NLR Family, Pyrin Domain-Containing 3 ProteinBrainAnimalsHumansMiceAllosteric SiteProteomicsDrug DiscoveryInflammasomes

Stichwörter der Autor:innen

NLRP3additional Area(s)allosteric modulationbiochemical pharmacologycross‐cutting areadrug discovery/target validationinflammasomeinflammation

Substanzen

NLR Family, Pyrin Domain-Containing 3 ProteinInflammasomes

Autor:innen und Institutionen

  • Vividion Therapeutics, San Diego, California, USA.

ORCID-Profile: Evelyn P Sievert

Zitieren

APA

Rogness, D. C., Sievert, E. P., Vartabedian, V. F., Bernard, S. M., Aitchison, E., Tao, W., Lindvall, M., Qian, J., Eissler, C. L., Nordin, B. E., Horning, B. D., Kingston, C., Lamb, K. N., Bell, J. C., Lu, B., Pollock, J., Shi, J., Khattri, R., Weinstein, D. S., …, & Simon, G. M. (2026). Chemoproteomic discovery of a brain‐penetrant, covalent NLRP3 inhibitor that binds a novel allosteric pocket. British Journal of Pharmacology. https://doi.org/10.1111/bph.70626

Vancouver

Rogness DC, Sievert EP, Vartabedian VF, Bernard SM, Aitchison E, Tao W, et al. Chemoproteomic discovery of a brain‐penetrant, covalent NLRP3 inhibitor that binds a novel allosteric pocket. British Journal of Pharmacology. 2026. doi:10.1111/bph.70626

BibTeX
@article{Rogness2026,
  author = {Rogness, Donald C and Sievert, Evelyn P and Vartabedian, Vincent F and Bernard, Steffen M and Aitchison, Erick and Tao, William and Lindvall, Mikaela and Qian, Jing and Eissler, Christie L and Nordin, Brian E and Horning, Benjamin D and Kingston, Cian and Lamb, Kelsey N and Bell, Joshua C and Lu, Bingwen and Pollock, Jonathan and Shi, Jun and Khattri, Roli and Weinstein, David S and Patricelli, Matthew P and Cook, Brian N and Simon, Gabriel M},
  title = {Chemoproteomic discovery of a brain‐penetrant, covalent NLRP3 inhibitor that binds a novel allosteric pocket},
  journal = {British Journal of Pharmacology},
  year = {2026},
  doi = {10.1111/bph.70626}
}
Kostenlos starten →